Patents by Inventor Tommy Liljefors

Tommy Liljefors has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GABAreceptor modulators
    Patent number: 8809355
    Abstract: The present invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABAA receptor modulator.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: August 19, 2014
    Assignee: Innovationspatent Sverige AB
    Inventors: Mogens Peter Cherly Nielsen, Tommy Liljefors, Jakob Alexander Nilsson, Olov A Sterner
  • Classes of GABAA/BZR ligands
    Patent number: 8481561
    Abstract: The present invention relates to novel GABAA/BzR ligands of the general formulas (I), (II) and (III) wherein R1 is selected from the group consisting of hydrogen, halogen, haloalkyl having 1-2 carbon atoms, alkoxy having 1 to 3 carbon atoms in the alkyl chain, alkyl having 1 to 3 carbon atoms, and nitro, and R2 is selected from the group consisting of hydrogen, halogen and alkyl having 1 to 2 carbon atoms, as well as the use of these compounds for treating anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals including pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: July 9, 2013
    Assignee: Innovationspatent Sverige AB
    Inventors: Mogens Peter Cherly Nielsen, Tommy Liljefors, Jakob Alexander Nilsson, Olov A Sterner
  • NEW CLASSES OF GABAA/BZR LIGANDS
    Publication number: 20110105553
    Abstract: The present invention relates to novel GABAA/BzR ligands of the general formulas (I), (II) and (III) wherein R1 is selected from the group consisting of hydrogen, halogen, haloalkyl having 1-2 carbon atoms, alkoxy having 1 to 3 carbon atoms in the alkyl chain, alkyl having 1 to 3 carbon atoms, and nitro, and R2 is selected from the group consisting of hydrogen, halogen and alkyl having 1 to 2 carbon atoms, as well as the use of these compounds for treating anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals including pharmaceutical compositions comprising the same
    Type: Application
    Filed: April 2, 2009
    Publication date: May 5, 2011
    Inventors: Mogens Nielsen, Tommy Liljefors, Jakob Nilsson, Olov Sterner
  • GABAA RECEPTOR MODULATORS
    Publication number: 20110092525
    Abstract: The resent invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABAA receptor modulator.
    Type: Application
    Filed: April 2, 2009
    Publication date: April 21, 2011
    Inventors: Mogens Nielsen, Tommy Liljefors, Jakob Nilsson, Olov Sterner
  • Novel Quinoxaline Derivatives and Their Medical Use
    Publication number: 20090286797
    Abstract: This invention relates to novel quinoxaline derivatives having medical utility, to use of the quinoxaline derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the quinoxaline derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to positive modulation of AMPA receptor mediated synaptic responses.
    Type: Application
    Filed: November 20, 2006
    Publication date: November 19, 2009
    Inventors: Dan Peters, Jeppe Kejser Christensen, Kasper Harpsøe, Tommy Liljefors